262

Otsuka American Pharmaceutical agreed to 1.7 million to settle multistate litigation alleging it engaged in off-label marketing of the schizophrenia drug Abilify and thus cased false claims to be submitted to state Medicaid programs. This was part of a larger 4 million settlement involving the federal government;